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Abstract: Phosphoramidate pro-nucleotides (ProTides) have revolutionized the field of anti-viral 
and anti-cancer nucleoside therapy, overcoming the major limitations of nucleoside therapies and 
achieving clinical and commercial success. Despite the translation of ProTide technology into the 
clinic, there remain unresolved in vivo pharmacokinetic and pharmacodynamic questions. Positron 
Emission Tomography (PET) imaging using [18F]-labelled model ProTides could directly address 
key mechanistic questions and predict response to ProTide therapy. Here we report the first 
radiochemical synthesis of [18F]ProTides as novel probes for PET imaging. As a proof of concept, 
two chemically distinct radiolabelled ProTides have been synthesized as models of 3′- and 2′-
fluorinated ProTides following different radiosynthetic approaches. The 3′-[18F]FLT ProTide was 
obtained via a late stage [18F]fluorination in radiochemical yields (RCY) of 15–30% (n = 5, decay-
corrected from end of bombardment (EoB)), with high radiochemical purities (97%) and molar 
activities of 56 GBq/μmol (total synthesis time of 130 min.). The 2′-[18F]FIAU ProTide was obtained 
via an early stage [18F]fluorination approach with an RCY of 1–5% (n = 7, decay-corrected from EoB), 
with high radiochemical purities (98%) and molar activities of 53 GBq/μmol (total synthesis time of 
240 min). 
Keywords: fluorination; ProTides; fluorine-18; radiolabelling; PET imaging 
 
1. Introduction 
Clinically approved nucleoside analogues occupy a unique place in drug therapy due to their 
ability to interfere in biosynthetic and metabolic pathways fundamental to aberrant cellular 
replication and growth. This is particularly apparent in conditions such as cancer [1] and viral 
infections [2], where nucleoside analogues are able to inhibit essential human or viral enzymes such 
as thymidylate synthase or ribonucleotide reductase. 
Despite their well-established value in drug therapy, nucleosides suffer from a number of 
drawbacks as therapeutic agents. Cellular entry of nucleosides through the outer cell membrane 
requires the active participation of concentrative and equilibrative nucleoside transporters; down-
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regulation of transporters in cancer cells for example constitutes a known drug resistance mechanism 
[3]. Following cellular uptake, nucleosides require activation via (normally) three successive enzyme-
mediated phosphorylation steps (Figure S1) [4]. The first kinase-mediated phosphorylation is most 
frequently the rate-limiting step prior to incorporation of the active therapeutic nucleotide tri-
phosphate within targets such as DNA/RNA. The requirements for transporter-mediated cellular 
entry and subsequent phosphorylation to the active form limit the therapeutic efficacy of nucleoside 
analogues. For example, the anticancer drug gemcitabine, widely used in pancreatic, non-small cell 
lung, ovarian and breast cancer therapy, is associated with levels of patient response as low as 20% 
[5]. 
Given the well-established drawbacks associated with nucleoside analogues, a great deal of 
research effort has been devoted towards the development of pro-nucleotides [6]. These nucleotide 
derivatives are defined as analogues able to by-pass the requirement for nucleoside membrane 
transporters and deliver a masked monophosphate that subsequently breaks down to a nucleotide 
monophosphate, or nucleotide derivative, within the cell. The most successful approach to this 
problem has been the phosphoramidate pro-nucleotides (ProTides) pioneered by McGuigan and 
colleagues at Cardiff University, U.K. [6]. The ProTide approach has revolutionized the field, 
delivering greatly enhanced concentrations of active nucleotide triphosphate within the diseased cell 
and improving clinical efficacy in important areas of anticancer and antiviral therapy. Examples of 
success in the antiviral field include the hepatitis C drug sofosbuvir (Gilead Sciences, Inc., Foster City, 
CA, USA), launched in 2014 to radically address the high level of unmet medical need in this common 
disease and achieving the status of the world’s top-selling drug worldwide following launch [7]. 
Within the anticancer field, several agents have progressed to clinical evaluation with very promising 
early clinical data. These include the gemcitabine ProTide NUC-1031 (Acelarin), discovered and 
developed through a collaboration between Cardiff University and NuCana plc. Acelarin is currently 
in Phase III clinical evaluation in pancreatic cancer [8]. 
Despite the emerging clear clinical advantages of the ProTide approach, evidence at the 
molecular level for the accumulation of ProTides at the in vivo site of action is currently lacking. A 
potential solution to this problem would be to label ProTides such that they were amenable to non-
invasive molecular imaging in vivo. In this regard, Positron Emission Tomography (PET) represents 
an attractive solution. PET imaging is a sensitive and rapidly emerging molecular imaging 
technology, widely used in prognostic and diagnostic clinical applications [9]. The basis of PET 
imaging is the incorporation of a radioactive PET-emitting nuclide into the biomarker or drug 
molecule of interest. The positron released then annihilates close to the site of emission by electron 
collision, generating two γ-rays (511 Kev) that are detected by coincidence measurement followed by 
3D image reconstruction. This annihilation event locates the site of origin of the target molecule with 
a high level of sensitivity [10]. The choice of PET isotope is crucial; amongst the many options 
available 18F has emerged as the non-metal nuclide of choice due to its intermediate half-life (110 
min), relatively low positron energy and exclusive positron mode of decay [11]. 
The incorporation of 18F into small molecules provides significant challenges for the 
radiochemistry community. The routinely utilized 18F-fluoride (dried and purified from aqueous 
fluoride solution from the cyclotron nuclear reactor source) is poorly nucleophilic, and electrophilic 
options derived from fluorine gas are disfavoured [12]. In addition, the half-life of 18F (110 min) means 
that 18F-incorporation normally has to occur at a late stage of multi-step syntheses, where purification, 
QC and formulation for patient administration is necessary within a few hours to generate a 
significant PET signal. These challenges are not insurmountable, and a range of 18F-labelled 
biomarkers and drugs have been produced and applied in clinical medicine. This is best exemplified 
by the routine use of the gold standard PET biomarker [18F]FDG (fluorodeoxyglucose) in cancer 
diagnosis, staging and monitoring of response to therapy [13]. 
Building on our previous experience of 18F-radiolabelling of nucleosides for PET imaging [14,15], 
we set out to apply our technology to the ProTide field. Here we report the first radiosynthetic routes 
to both 3′- and 2′-fluorinated model ProTides. Application of this technology could help to improve 
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both diagnostic and prognostic applications of ProTide technology in the clinic, with profound 
implications for this exciting area of anticancer and antiviral therapy. 
2. Results and Discussion 
As a proof of concept, two [18F]-radiolabelled ProTides have been synthesised. The 
[18F]FLuoroThymidine (FLT) ProTide (1) and the [18F]Fluoro-Iodo-ArabinofuranosylUracil (FIAU) 
ProTide (2) (Figure 1) were our chosen model standards for 3′-fluorinated and 2′-fluorinated 
ProTides, respectively. 
 
Figure 1. Structures of the [18F]FLuoroThymidine (FLT) ProTide (1) and [18F]Fluoro-Iodo-
ArabinofuranosylUracil (FIAU) (ProTide (2). 
2.1. [18F]FLT- a Prototypical 3′-fluorinated ProTide 
[18F]FLT, a 3′-fluorinated nucleoside, is an established PET imaging agent used as a tumour 
proliferation biomarker [16]. Synthetic approaches involving a late stage [18F]-fluorination of different 
precursor molecules of [18F]FLT have been extensively studied [15]. Moreover, our group has 
previously reported the synthesis of a series of (non-radiolabelled) FLT ProTides that showed a 
relatively safe toxicological profile compared to the parent nucleoside as well as moderate anti-HIV 
activity [17]. For these reasons, [18F]FLT ProTide has been selected as a target compound in this study 
to represent the class of 3′-fluorinated ProTides. The choice of the phenol group as aromatic moiety 
and the L-alanine ethyl ester as the amino acid ester on the phosphoramidate moiety were dictated 
by the accessibility of the starting materials as well as the favourable yields associated with the 
coupling reactions involved in the synthesis [17]. The radiochemical synthesis of [18F]FLT ProTide (1) 
was planned accordingly taking into account the short half-life of fluorine-18 (110 min), with the 
[18F]fluorination occurring at a late stage in the synthesis (Scheme 1). The challenge for this 
radiosynthetic plan was therefore to identify a precursor molecule with a balanced reactivity towards 
the weakly nucleophilic [18F]fluoride with stability in the harsh thermal conditions used for the 
radiolabelling step. A series of good leaving groups {methanesulfonyl (mesyl); p-toluenesulfonyl 
(tosyl); p-nitrophenylsulfonyl (nosyl)} for the key nucleophilic fluoride displacement reaction 
(intermediates 4–7) were selected for reaction optimization. 
 
Scheme 1. Late stage fluorination approach for the synthesis of the [18F]FLT ProTide (1). 
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A cold non-radioactive standard of the [18F]FLT ProTide was synthesized according to 
established ProTide chemistry protocols (Scheme 2) [18]. The phosphorochloridate intermediate (10) 
was first obtained from the L-alanine ethyl ester hydrochloride salt and the commercially available 
dichlorophosphate (9) using triethylamine as base. Compound 10 was obtained as a mixture of 
diastereoisomers because of the formation of a new stereocenter at the phosphorus atom in a 1:1 Rp: 
Sp ratio. Commercially available FLT (8; Carbosynth) was then reacted with the phosphorylating 
reagent using tert-butyl magnesium chloride (t-BuMgCl) as a hindered base. The desired product (11) 
was obtained as a mixture of diastereoisomers (1:1 Rp:Sp) with a yield of 24% and was used as 
standard analytical control for studies of the radiochemical synthesis of [18F]FLT ProTide. 
 
Scheme 2. Synthesis of the cold standard FLT ProTide. Reagents and conditions: (a) L-
alanine ethyl ester hydrochloride salt, Et3N, −78 °C to rt, anh. CH2Cl2, 3 h, 92%; (b) t-
BuMgCl, anh. THF, 18 h, 24%. 
Stability studies were performed on the non-radioactive standard to test the susceptibility of the 
ProTide phosphoramidate to the high temperatures used during the [18F]fluorination. The dynamic 
behaviour of the phosphoramide moiety was therefore monitored at temperatures ranging from 50 
°C to 120 °C. 31P NMR spectroscopy is particularly well suited for this purpose considering the 
characteristic chemical shifts at around δ 4 ppm of the phosphoramidate backbone of the FLT ProTide 
[17]. The two 31P NMR peaks of the diasteroisomeric mixture were observed to be stable when the 
compound was heated up to 120 °C, confirming its stability to the high temperatures that were used 
during the radiolabelling step (see Supplementary Materials, Figure S2). 
2.1.2. Synthesis of a Series of Organophosphates as Precursor Molecules of the [18F]FLT ProTide 
To design a late stage fluorination for the class of 3′-substituted ProTides, a multi-step synthesis 
was performed to obtain a thymidine based ProTide with an anhydroxylic group in the 3′-β position 
of the ribose ring. The first step consisted of the formation of the 3′-β hydroxy intermediate (13) via a 
Mitzunobu reaction [18] followed by hydrolysis of the intermediate compound 12 to obtain inversion 
of the stereochemistry of the hydroxylic group at the 3′ position of the thymidine. The intermediate 
14 was again synthesised following the standard procedure previously described. N-
methylimidazole (NMI) was used at this time as the coupling reagent because of the presence of the 
free hydroxylic group in the 3′-position that could compete with the 5′-OH group for the 
phosphorylation [19]. 
The hydroxyl group at the 3′-β position of 14 is a poor leaving group for the nucleophilic 
substitution reaction with anhydrous [18F]fluoride. Therefore, the 3′-hydroxyl group was selectively 
activated with a series of sulfonic esters to produce good leaving groups (4–6) for reaction with the 
weakly nucleophilic [18F]fluoride, in accordance with literature precedent [11,20]. The intermediate 
14 was reacted with mesyl chloride, tosyl chloride and nosyl chloride respectively in presence of a 
weak base such as pyridine or Et3N with or without AgOTf as a catalyst (Scheme 3). To improve the 
stability of precursor 6 and avoid competitive cyclization/elimination reaction upon reaction with the 
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fluorine-18 [21], protection of the NH group of the pyrimidine ring was performed with the tert-
butoxycarbonyl group (Boc). Surprisingly, the major product of the reaction observed was the di-
protected ProTide (7) bearing Boc groups at both the NH of the pyrimidine ring and the 
phosphoramidate moiety. The abundance of the di-Boc protected compound compared to the mono-
protected product as result of the Boc-protection reaction, together with the need for a stable 
fluorination precursor, led us to choose the di-Boc protected product (7) for the following radio-
fluorination step. 
 
Scheme 3. Synthetic procedure for the mesyl, tosyl and nosyl precursors. Reagents and 
conditions: (a) PPh3, DIAD, anh. CH3CN, −20 °C to 0 °C, 5 h, 52%; (b) L-alanine ethyl ester 
hydrochloride salt, Et3N, −78 °C to rt, anh. CH2Cl2, 3 h, 92%; (c) NaOH (1.5 M), CH3OH, 90 
°C, 3 h, 64%; (d) Phosphorochloridate, NMI, anh. THF, 25 °C, 18 h, nitrogen atm, 18.4%; (e) 
Mesyl chloride, Et3N, anh. CH2Cl2, nitrogen atm., 0 °C to 25 °C, 1.5 h, 29.5%; (f) Tosyl 
chloride, pyridine, AgOTf, 0 °C to rt, 2 h, 35%; (g) Nosyl chloride, pyridine, AgOTf, 0 °C to 
rt, 2 h, 60%; (h) Di-tert-butyldicarbonate, pyridine, rt, 16 h, 56%. 
2.1.3. Radiochemical Synthesis of the [18F]FLT ProTide 
The Eckert & Ziegler modular lab was used for the [18F]-fluorination following the schematic 
described in the supplementary material (Figure S3). K [18F]F/K222/K2CO3 was used as the fluorinating 
agent and a series of solvents and temperatures were tested to establish the best conditions for the 
radio-fluorination. The methanesulfonyl (mesyl) precursor (4) and the p-toluenesulfonyl (tosyl) 
precursor (5) did not give the expected [18F]-radiolabelled compound as observed from the radio 
HPLC chromatograms (Figures S4 and S5 and Tables S1 and S2). The p-nitrobenzenesulfonate (nosyl) 
precursor 6 was, as expected, the most reactive among the three organosulfonate leaving groups for 
the SN2 reaction with the weak nucleophile [18F]fluoride [11], but lacked stability with the formation 
of multiple radiolabeled polar compounds and a radiochemical yield < 1% as determined by 
analytical HPLC (Figure S6 and Table S3). 
To increase the stability of the precursor, two Boc protecting groups were added, as previously 
described, leading to the formation of compound 7. This precursor proved to be the best substrate for 
[18F]-fluorination. Radio-HPLC showed a major product (15) with a retention time at around 15 min 
(Figure S7). This suggested that the desired Boc radiolabelled product was formed therefore 
supporting the hypothesis that the Boc double protection provides improved stability for the nosyl 
precursor. The deprotection step was then carried out by adding 2 N HCl for 10 min at 95 °C [22] and 
the final compound was then neutralised with a 2 M NaOH solution. Gratifyingly the major product 
of this reaction was the [18F]FLT ProTide (1) with few other minor by-products (Scheme 4, Figure S8). 
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Scheme 4. 18F-fluorination of the Boc protected nosyl derivative 7 and deprotection. 
Reagents and conditions: (a) 18F−, Kryptofix, anh. CH3CN, 90 °C, 30 min.; (b) 2 N HCl, 95 °C, 
10 min. 
The compound was then purified by semi-preparative HPLC (Phenomenex Synergi 4μ Hydro-
RP 80, C-18, 10 × 250 mm) and was eluted after 35 min at a flow rate of 3.5 mL/min using 30% 
CH3CN/70% H2O as the mobile phase. To confirm the identity of the 18F-product (1), an aliquot of the 
purified sample was analysed by HPLC (Phenomenex Synergi 4μ Hydro-RP 80, C-18, 4.6 × 250 mm) 
via co-elution with the cold standard. The 18F-product showed a Rt of 9.5 min and the cold standard 
co-injected eluted at a Rt of 9.2 min (Figure 2) confirming the identity of the [18F]FLT ProTide (1). 
Radiochemical reactions were carried out using starting activities between 1.5–8 GBq, leading to final 
product activities of 300–580 MBq in a good radiochemical yield (RCY) of 15–30% (n = 5, decay-
corrected from end of bombardment (EoB)). High radiochemical purities (≥97%) and molar activities 
of 56 GBq/μmol were obtained, and the total synthesis time was 130 min after the end of 
bombardment (EoB). 
 
(a) 
 
O
O
N
N
O
ONosP
O
O
N
OO
O
O
O
N
N
O
P
O
O
N
OO
O
18F
a
O
O
HN
N
O
P
O
O
HN
OO
O
18F 1
b
7 15
Boc Boc
BocBoc
Molecules 2020, 25, 704 7 of 18 
 
(b) 
Figure 2. HPLC of the [18F]FLT ProTide (1). (a) Radioactive chromatogram of the purified 
[18F]FLT ProTide with Rt of 9.5 min; (b) UV chromatogram of the reaction mixture co-spiked 
with the cold standard (Rt: 9.2 min). HPLC system: 90% H2O/10% CH3CN, to 50% H2O/50% 
CH3CN. 
2.2. [18F]FIAU - A Prototypical 2′-Fluorinated ProTide 
2′-deoxy-2′-[18F]fluoro-1-β-D-arabinofuranosyl-5-iodouracil ([18F]FIAU), is a PET biomarker 
used for imaging HSV1-tk gene expression in biological processes including transcriptional 
regulation, lymphocyte migration and stem-cell tracking [23]. Building on previous developed 
radiosyntheses of this tracer for PET imaging, we decided to synthesise a ProTide of [18F]FIAU (2) as 
a model of the class of the 2′-fluorinated ProTides [10] introducing 18F early in the synthetic sequence 
as outlined in Scheme 5. 
 
Scheme 5. Synthetic approach for the radiosynthesis of the [18F]FIAU ProTide (2). 
2.2.1. Synthesis of the Non-Radioactive FIAU ProTide Standard  
A cold standard of FIAU ProTide (21) was synthesised following the synthesis outlined in 
Scheme 6. The commercially available compound 18 was firstly iodinated at the C-5 position upon 
reaction with iodine and cerium ammonium nitrate to give compound 19 under previously reported 
conditions [24]. The ProTide 21 was synthesised using methodology described above with the 
exception that the L-alanine ethyl ester was here replaced by a benzyl ester (using compound 20). 
The phosphoramidate 21 was obtained as a diasteroisomeric mixture for co-injection with the 
radiolabelled counterpart, the [18F]FIAU ProTide, to confirm its identity by HPLC. 
 
Scheme 6. Synthesis of the non-radioactive standard FIAU ProTide (21). Reagents and 
conditions: (a) I2, Ceric ammonium nitrate, ACN, 75 °C, 1 h, 60%; (b) L-alanine benzyl ester 
hydrochloride salt, Et3N, −75 °C to rt, anh. CH2Cl2, 3 h, 88%; (c) NMI, anh. THF, 0 °C to rt, 
16 h, 10%. 
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2.2.2. Radiochemical Synthesis of the [18F]FIAU ProTide 
The first step consisted of the radioactive fluorination of the commercially available sugar 16 
bearing a triflate as leaving group according to literature precedent ([18F]fluoride, Kryptofix, anh. 
CH3CN, 95 °C) [25]. The reaction was again carried out using the E&Z modular lab. After purification 
with an alumina sep-pak [26], the radiolabelled sugar (17) was used for the next step without further 
purification. When an aliquot of the radioactive mixture was co-spiked with a cold standard (Sigma 
Aldrich), it showed the same retention time at around 3 min (Figure S10). 
The second step consisted in the protection of the base moiety 22 with hexamethyldisilazane and 
the catalyst trimethylsilyl trifluoromethanesulfonate (TMSOTf) [27] to obtain compound 23 that was 
coupled with the radiolabelled sugar (17) without further purification. The glycosylation reaction led 
to the formation of two anomers following removal of the TMS groups under basic conditions, the β-
anomer ([18F]FIAU) (24) and the α-anomer in a ratio 2:1 (Figure S10). Attempts to increase the speed 
of the reaction by either reducing the time or using a combination of catalysts (TMSOTf and SnCl4) 
led to incomplete conversion into the final product or favoured the formation of the α-anomer (ratio 
β:α = 1:1.3), as shown in Table 1 [27,28]. Therefore, based on these attempts to optimise the reaction 
conditions, the synthetic pathway in Scheme 7 was established as the most suitable for synthesis of 
[18F]FIAU 24. 
Table 1. Tentative optimization of the glycosylation reaction. 
Solvent Temperature Time Catalyst Ratio β:α 
CH3CN 85 °C 30 min TMSOTf Incomplete 
CH3CN 85 °C 45 min TMSOTf Incomplete 
CH3CN 85 °C 1 h TMSOTf 2:1 
CH3CN 95 °C 30 min TMSOTf Incomplete 
CH3CN 85 °C 15 min TMSOTf+SnCl4 [24] 1:1.3 
 
Scheme 7. Radiochemical synthesis of [18F]FIAU (24). Reagents and conditions: (a) 18F-, 
Kryptofix, anh. CH3CN, 95 °C, 30 min; (b) Hexamethyldisilazane, TMSOTf, anh. 
dichloroethane, 85 °C, 2 h; (c) anh. CH3CN, 85 °C, 1 h; (d) NaOCH3/CH3OH, 85 °C, 10 min. 
Finally the last step consisted of the coupling between the [18F]FIAU (24) and the appropriate 
phosphorochloridate previously synthesised according to the standard NMI promoted procedure 
[19]. The phosphoramidate reaction between phosphorochloridate and nucleoside under non-
radioactive conditions is reported in the literature as a room temperature reaction over 16h [19]. 
However, this procedure would not be suitable for a reaction as time sensitive as one involving the 
short-lived radionuclide fluorine-18 (t1/2 = 109.7 min.). For this reason, we developed an assay to 
observe the progress of the phosphoramidate bond formation. The substrate of this assay was the 
non-radioactive FIAU and the reaction was monitored via 31P NMR spectroscopy and HPLC 
chromatography. Surprisingly we observed almost complete conversion into the ProTide after 15 min 
when the reaction was conducted at mild temperatures (50 °C) to then reach a steady state at around 
30 min (Figure 3). 
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Figure 3. Conversion rate of FIAU (19) into FIAU ProTide (21): % conversion to FIAU 
ProTide during the coupling reaction was calculated over time at 50 °C using 31P NMR 
spectroscopy and analytical HPLC chromatography. 
We therefore applied the same conditions for the radioactive reaction and observed formation 
of the final compound (2) at 50 °C after 15–20 min. (Scheme 8). 
 
Scheme 8. Synthesis of the [18F]FIAU ProTide. Reagents and conditions: (a) NMI, anh. THF, 
50 °C, 20 min. 
Satisfyingly, when an aliquot was taken to perform an analytical HPLC evaluation, [18F]FIAU 
ProTide (2) was observed to be the main product of the reaction (Figure S11). The product was then 
isolated via semi preparative HPLC and was eluted after 23 min at a flow rate of 3.5 mL/min using 
50% CH3CN/50% H2O as the mobile phase. An aliquot of the purified sample was analysed by 
analytical HPLC via co-elution with the non-radioactive standard (Figure 4). 
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(b) 
Figure 4. HPLC of [18F]FIAU ProTide. (a) Radioactive chromatogram of the purified 
[18F]FIAU ProTide with Rt of 12.3 min; (b) UV chromatogram of the [18F]FIAU ProTide co-
spiked with the non-radioactive standard. (Rt of non-radioactive standard: 12.2 min). HPLC 
system: 90% H2O/10% CH3CN to 50% H2O/50% CH3CN. 
Radiochemical reactions were carried out using starting activities between 7–15 GBq, leading to 
final product activities of 8–46 MBq in RCY of 1–5% (n = 7, decay-corrected from end of bombardment 
(EoB)), with high radiochemical purities (98%) and molar activities of 53 GBq/μmol. The total 
synthesis time was 240 min after the end of bombardment (EoB), within the acceptable range of just 
over two half-lives for future pre-clinical/clinical applications. 
3. Materials and Methods 
3.1. General Non-Radioactive Chemistry: Reagents and Analytical Methods 
All the reagents and anhydrous solvents were purchased from Sigma-Aldrich. FLT was 
purchased from Carbosynth Ltd. (Berkshire, UK). Fluka silica gel (35–70 mm) was used as stationary 
phase for column chromatography. 1H NMR spectra were acquired for all known compounds 
whereas for novel compounds 1H NMR, 31P NMR, 13C NMR, MS and HPLC data were acquired. 1H 
NMR were measured using a Bruker Advance Ultra Shield spectrometer (500 MHz) at ambient 
temperature. Data were recorded as follows: chemical shift in δ ppm from internal standard 
tetramethylsilane; multiplicity (s = singlet; d = doublet; t = triplet; m = multiplet); coupling constant 
(Hz); integration and assignment. 13C NMR spectra were measured using a Bruker Advance Ultra 
Shield spectrometer (125 MHz) at ambient temperature. Chemical shifts were recorded in ppm from 
the solvent resonance used as the internal standard (e.g., CDCl3 at 77.00 ppm). 31P NMR spectra were 
recorded on a Bruker Advance Ultra Shield spectrometer (202 MHz) at ambient temperature. 19F 
NMR spectra were recorded on a Bruker Advance Ultra Shield (474 MHz) spectrometer at ambient 
temperature. High-performance liquid chromatography (HPLC) analysis was conducted on an 
Agilent Technology 1200 Series System at the PET imaging centre in Cardiff (PETIC) with an 
analytical reversed phase column (Phenomenex Synergi 4μ Hydro-RP 80, C-18, 4.6 × 250 mm). Thin-
layer chromatography (TLC) was conducted on pre-coated silica gel 60 GF254 plates. Mass 
spectrometry analysis (LC-ESI-MS) was performed on a Bruker micro-TOF and with an Agilent 6430 
T-Quadrupole spectrometer. High-resolution mass spectrometry (ESI-HRMS) was determined at the 
EPSRC National Mass Spectrometry facility at Swansea University (Swansea, UK). 
3.2. General Radiochemistry: Source, Equipment and Analytical Methods 
[18F]Fluoride was produced in an IBA Cyclon 18/9 cyclotron using the 18O(p,n)18F nuclear 
reaction. 18O-Enriched water (enrichment grade 98%, 2.2 mL, Nukem GmbH, Alzenau, Germany) was 
Molecules 2020, 25, 704 11 of 18 
 
irradiated with 18 MeV protons. Radiofluorinations were performed on an Eckert & Ziegler module 
system. The drying procedures were performed with a vacuum pump N820 (Neuberger, Freiburg, 
Germany). Semi-prep HPLC (Phenomenex Synergi 4μ Hydro-RP 80, C-18, 10 × 250 mm) with a 
smartline pump 100–126 connected to the Eckert & Ziegler module system was used for the 
purification of the radiolabelled products. QMA and Al sep-pak (Waters corp., Milford, MA, USA) 
were used for purification of fluorine-18 intermediates. HPLC analytical evaluation was conducted 
on an Agilent Technology 1200 Series System with an analytical reversed phase column (Phenomenex 
Synergi 4μ Hydro-RP 80, C-18, 4.6 × 250 mm) coupled with a RAM/RAM Model 4 detector (Lablogic 
System, Ltd., Sheffield, UK) for radio-HPLC purposes. 
3.3. Procedures and Spectroscopic Data for the Synthesis of the [18F]FLT-ProTide 
Synthesis of (2S)-ethyl-2-((chloro(phenyl)phosphoryl)amino)propanoate (10). C11H15ClNO4P; MW: 291.6. 
Compound 10 was synthesized according to standard procedure [19]. Anhydrous triethylamine (2 
eq; 0.662 mL; 0.480 g; 4.74 mmol) was added to the phenyldichlorophosphate (9) (1 eq; 0.354 mL; 0.500 
g; 2.37 mmol) and L-alanine ethyl ester hydrochloride salt (1 eq; 0.364 g; 2.37 mmol) in anhydrous 
CH2Cl2 (5 mL) to obtain the final product 10 as a yellowish oil that was used without further 
purification. Yield: 92%. 1H NMR (500 MHz, CDCl3): δ 7.35–7.41 (m, 2H, Ar-H), 7.21–7.30 (m, 3H, Ar-
H), 4.53 (m, 1H, NH), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 1.51 (m, 3H, CH3), 1.23 (m, 3H, CH3). 31P 
NMR (202 MHz, CDCl3): δ 7.71, 8.05. Spectroscopic data in agreement with literature [29–31]. 
Synthesis of (2S)-ethyl2-(((((2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (11). C21H27FN3O8P, MW: 499.4. 
FLT (8) (1 eq; 0.100 g; 0.41 mmol) in anhydrous THF, was reacted with tBuMgCl (1.5 eq; 0.08 mL) 
under nitrogen atmosphere. The reaction mixture was stirred at rt for 30 min. A solution of the 
phosphorochloridate 10 (2 eq; 0.239 g; 0.82 mmol) in anhydrous THF was then added dropwise and 
the reaction mixture was left to stir overnight. The solvent was then evaporated under reduced 
pressure and the residue was purified by silica gel column chromatography (CH2Cl2/CH3OH from 
100% CH2Cl2 to 95% CH2Cl2) to give the FLT ProTide (11) as a yellowish oil. Yield: 23.5%. Rf: 0.44 in 
90% CH2Cl2/10% CH3OH TLC system. 1H NMR (500 MHz, CDCl3): δ 8.60 (br s, 1H, NH), 7.55 (s, 1H, 
H-6), 7.33–7.41 (m, 2H, Ar-H), 7.20–7.29 (m, 3H, Ar-H), 6.23–6.30 (m, 1H, H-1′), 5.33 (m, 1H, H-3′), 
4.43–4.53 (m, 2H, NH, H-4′), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 3.35-3.51 (m, 2H, H-5′, H-5”), 2.48–
2.51 (m, 1H, H-2”), 2.55–2.33 (m, 1H, H-2′), 1.93–1.74 (m, 3H, CH3, thy), 1.30–1.18 (d, J = 6.9, CH3-ala). 
19F NMR (479 MHz, CDCl3): δ −173.70, −175.20. 31P NMR (202 MHz, CDCl3): δ 4.34, 4.12. MS (ESI+): 
498.1 [M − H+]. HPLC: Rt: 10.8 min; Purity > 96%; [Gradient: (0′) 95%H2O/5% CH3CN − (5′) 50% 
H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN]. Spectroscopic data in 
agreement with literature [17]. 
Synthesis of (3R,5R)-3-(hydroxymethyl)-8-methyl-2,3-dihydro-5H,9H-2,5-methanopyrimido[2,1-
b][1,5,3]dioxazepin-9-one (12). MF: C10H12N2O4; MW: 224.22. Thymidine (3) (1 eq, 0.250g, 1.32mmol) 
and triphenylphosphine (Ph3P) (2 eq, 0.541 g, 2.64 mmol) were suspended in anhydrous acetonitrile 
(20 mL) and cooled down to −15 °C. Diisopropylazadicarboxylate (DIAD) (2 eq, 0.406 mL, 0.417 g, 
2.64 mmol) was then added dropwise maintaining the temperature below −5 °C with vigorous 
stirring. The reaction was allowed to stir for 5h at 0 °C and then again cooled down to −20 °C. Cold 
ethyl acetate (20 mL) was added and the reaction was stirred for a further 15 min. A white precipitate 
was formed and was collected by Buchner filtration. The filtrate was washed with cold ethyl acetate 
and evaporated to dryness. The resulting crude compound was purified by silica gel column 
chromatography using 90% CH2Cl2/10% CH3OH as eluent to obtain the product 12 as a white solid. 
Yield: 52%. Rf: 0.5. 1H NMR (500 MHz, DMSO-d6): δ 7.55 (d, J = 1.2, 1H, ArH), 5.80 (d, J = 3.9, 1H, H-
1′), 5.23 (brs, 1H, H-3′), 5.01 (t, 1H, 5′-OH), 4.20 (m, 1H, H-4′), 3.51 (m, 2H, H-5′, H-5”), 2.55 (d, J = 1.2, 
H-2′,1H), 2.47 (ddd, J1,8 = 19.0, J1,4 = 6.7, J1,2 = 3.0, 1H, H-2”), 1.76 (d, J = 1.1, 3H, CH3). Spectroscopic 
data in agreement with literature [32]. 
Synthesis of 1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (13). MF: C10H14N2O5; MW: 242. 3′-anhydrothymidine (12) (0.200 g; 0.892 mmol) in 
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aq. 1.5 M NaOH (3.33 mL) was stirred in methanol (30 mL) under reflux for 3 h. Upon heating, the 
solution changed colour from clear to golden-brown. The reaction was monitored by TLC 
chromatography. When the conversion into the final product was confirmed, the solvent was 
evaporated under reduced pressure. The resulting crude compound was purified by silica gel column 
chromatography (CH2Cl2/CH3OH gradient from 100% to 90% of CH2Cl2) to obtain the final product 
(13) as a white powder. Yield: 64%. Rf: 0.4 in 90% CH2Cl2/10% CH3OH TLC system. 1H NMR (500 
MHz, DMSO-d6): δ 11.24 (s, 1H, NH), 7.78 (s, 1H, H-6), 6.07 (dd, J = 8.5, 2.44, 1H, H-1′), 5.25 (d, J = 3.35, 
1H, 3′-OH), 4.67 (t, J = 5.49, 1H, 5′-OH), 4.23 (m, 1H, H-3′), 3.60–3.84 (m, 3H, H-4′, H-5′ and H-5”), 
2.55–2.59 (m, 1H, H-2”), 1.84 (dd, J = 14.95, J = 2.14, 1H, H-2′), 1.76 (s, 3H, CH3). Spectroscopic data in 
agreement with literature [32]. 
Synthesis of ((2S)-ethyl-2-(((((2R,3R,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (14). MF: C21H28N3O9P; MW: 
497.4. Compound 14 was synthesised according to standard procedure [16]. 1-(2-deoxy-β-
lyxofuranoxyl thymidine) (13) (1 eq; 0.175 g; 0.721 mmol) was reacted with NMI (5 eq; 0.287 mL; 0.297 
g, 3.62 mmol) and ethyl-(2-chloro(phenyl)phosphorylamino)propanoate (10) (3 eq; 0.633 g; 2.17 
mmol) to obtain a crude residue that was purified by silica gel column chromatography (97% 
CH2Cl2/3% CH3OH) to afford the final compound 14 as a white solid. Yield: 18.4%. Rf: 0.4. 1H NMR 
(500 MHz, CDCl3): δ 7.58 (d, J = 7.0, 1H, H-6), 7.35–7.43 (m, 2H, Ar-H), 7.20–7.29 (m, 3H, Ar-H), 6.25–
6.32 (m, 1H, H-1′), 5.22 (m, 1H, 3′-OH), 4.94 (m, 1H, H-3′), 4.31–4.52 (m, 2H, NH, H-4′), 3.95–4.03 (m, 
1H, CH), 3.68 (d, J = 7.0, 2H, CH2-ester), 3.35 (d, J = 16.0, 2H, H-5′, H-5”), 2.48–2.51 (m, 1H, H-2”), 2.09–
2.25 (m, 1H, H-2′), 1.85 (d, J = 10.1, 3H, CH3-thy), 1.23 (m, 3H, CH3-ala), 1.16 (d, J = 7.2, 3H, CH3-ester). 
31P NMR (200 MHz, CDCl3): δ 5.34, 4.98. 
Synthesis of (2S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
((methylsulfonyl)oxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (4). MF: 
C22H30N3O11PS; MW: 575.5. Triethylamine (10 eq; 1.06 mL; 0.769 g; 7.6 mmol) and mesyl chloride (4 
eq; 0.235 mL; 0.348 g; 3.04 mmol) were reacted with a solution of compound 14 (1 eq; 0.378 g; 0.76 
mmol) in anhydrous CH2Cl2 (20 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min and 
then warmed to rt and stirred for 1.5 h. The crude mixture was diluted with sat. NaHCO3 solution 
and extracted with CH2Cl2. After drying over Na2SO4, the solution was reduced under reduced 
pressure and the resulting crude compound was purified by silica gel column chromatography 
(CH2Cl2/CH3OH gradient from 100% CH2Cl2 to 95% CH2Cl2) to give the product 4 as a white solid. 
Yield: 29.5%. Rf: 0.45 in 90% CH2Cl2/10% CH3OH TLC system. 1H NMR (500 MHz, CDCl3): δ 8.93–
8.96 (s, 1H, NH, thy), 7.33–7.32 (d, J = 7.0, 1H, H-6), 7.24–7.28 (m, 2H, Ar-H), 7.10–7.15 (m, 3H, Ar-H), 
6.23–6.21 (m, 2H, H-1′), 5.19–5.15 (s, 1H, NH-ala), 3.84–4.37 (m, 7H, H-3′, H-4′, CH, H-5′, H-5”, CH2-
ethyl), 2.96–3.01 (s, 3H, SO2CH3), 2.72–2.75 (m, 1H, H-2”), 2.38–2.42 (m, 1H, H-2′), 1.87 (d, J = 1.2, 3H, 
CH3-thy), 1.28–1.33 (m, 3H, CH3-ala), 1.19–1.16 (m, 3H, CH3-ethyl). 13C NMR (125 MHz, CDCl3) δ 
173.7–173.4 (C=O, acetyl), 163.6 (C-2), 150.42 (C-1), 135.1 (C-4), 129.8 (C-2; C-6Ar), 125.2 (C-4Ar), 120.2 
(C-3; C-5Ar), 111.6 (C-3), 83.5 (C-1′), 79.9 (C-3′), 77.3 (C-4′), 63.7 (C-5′), 61.7 (CH2-ethyl), 50.8 (CH-ala), 
39.2 (C-2′), 38.8 (CH3-mesyl), 21.34 (CH3-ethyl), 14.04 (CH3-ala), 12.76 (CH3-thy). 31P NMR (202 MHz, 
CDCl3): δ 2.92, 2.63. MS(ESI+): 576.2 [M + H+]. HPLC: Rt: 13.2 min; Purity > 98%; [Gradient: (0′) 95% 
H2O/5% CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% 
CH3CN]. 
Synthesis of (2S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
(tosyloxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (5). MF: C28H34N3O11PS; 
MW: 651.6. To a solution of compound 14 (1 eq; 0.181 g; 0.364 mmol) in pyridine (5 mL), tosyl chloride 
(2 eq; 0.138 g; 0.727 mmol) and silver trifluoromethanesulfonate (AgOTf) (2 eq; 0.186 g; 0.727 mmol) 
were added at 0 °C. The reaction was stirred for 1 h and then slowly allowed to warm to rt and stirred 
for another 2 h. The reaction mixture was then diluted with EtOAc, filtered, and the filtrate was 
washed with H2O and brine. The organic layer was dried over anhydrous Na2SO4 and the solvent 
was evaporated under reduced pressure. The crude residue was purified by silica gel column 
chromatography (95% CH2Cl2/5% CH3OH) to furnish the tosylated compound 5 as a yellowish solid. 
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Yield: 35%. Rf: 0.55. 1H NMR (500 MHz, CDCl3) δ 7.76–7.75 (d, J = 1.9, 1H, H6 Ar), 7.34 (dd, J = 15.7, 
8.6, 4H, Ar-H tosyl), 7.27–7.17 (m, 5H, Ar), 6.19–5.20 (td, J = 7.8, 2.9, 1H, H-1′), 4.45–3.74 (m, 10H), 
2.72–2.61 (m, 1H, CH-ala), 2.46 (s, 3H, CH3, tosyl), 1.85 (s, 3H, CH3, thy), 1.39 (t, J = 7.2 Hz, 3H, CH3, 
ethyl), 1.31 (m, 3H, CH3-ala). 13C NMR (126 MHz, CDCl3) δ 173.65, 173.59 (C-ala), 163.52 (C1-thy), 
150.58, 150.53 (C3-thy), 150.25, 150.19 (C1-tosyl), 145.99, 145.98 (C1-phenyl), 135.04, 134.95 (CH-thy), 
133.05, 132.90 (C4-tosyl), 130.27, 130.21 (CH, C2, C6-tosyl), 129.75, 129.70 (CH, C2, C6-phenyl), 127.64, 
127.58 (CH, C4-phenyl), 125.10, 120.35 (CH, C3, C5-phenyl), 120.31, 120.21 (CH, C3, C5-tosyl), 111.15, 
110.98 (C3-thy), 84.22, 83.99 (CH, C1′), 80.96, 80.90 (CH, C3′), 80.72, 80.66 (CH, C4′), 63.89, 63.85 (CH2, 
C5′), 63.33, 63.29 (CH2, ethyl), 50.39, 50.38 (CH, ala), 39.03 (CH2, C3′), 21.69, 21.00 (CH3-ethyl), 20.96, 
20.95 (CH3-tosyl), 14.12 (CH3, ala), 12.49, 12.44 (CH3-thy). 31P NMR (202 MHz, CDCl3) δ 2.78, 2.66. MS 
(ESI)+: 652.2 [M + H+]; 674.1 [M + Na+]. HPLC: Rt: 16.03 min; Purity > 98%; [Gradient: (0′) 95% H2O/5% 
CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN]. 
Synthesis of (S)-ethyl-2-(((((2R,3R,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-(((4-
nitrophenyl)sulfonyl)oxy)tetrahydrofuran-2yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (6). MF: 
C27H31N4O13PS; MW: 682.5. The ProTide 14 (1 eq; 1.16 g; 2.34 mmol) was dissolved in pyridine (20 
mL) at 0 °C. 4-nitrobenzenesulfonylchloride (nosyl chloride) (2 eq; 1.06 g; 4.79 mmol) and silver 
trifluoromethanesulfonate (AgOTf) (2 eq; 1.23 g; 4.79 mmol) were added and the reaction mixture 
was stirred at 0 °C. After 1h the reaction mixture was allowed to slowly warm to rt and stirred for 
another 2 h. The reaction mixture was then diluted with EtOAc, filtered, and the filtrate was washed 
with H2O and brine. The organic layer was dried over anhydrous Na2SO4 and the solvent was 
evaporated under reduced pressure. Purification of the crude residue was accomplished by silica gel 
column chromatography (95% CH2Cl2/5% CH3OH) to give the desired compound 6 as a yellowish 
solid. Yield: 60%. Rf: 0.6. 1H NMR (500 MHz, CDCl3) δ 8.77–8.67 (s, 1H, NH, thy), 8.41–8.39 (d, J = 2.2, 
2H-Ar, nosyl), 8.14–8.08 (m, 2H-Ar, nosyl), 7.71 (ddd, J = 7.6, 4.7, 1.7, 1H, H6), 7.42–7.30 (m, 5H-Ar), 
6.28–5.28 (m, 1H-H-1′), 4.51–3.75 (m, 7H), 2.79–2.46 (m, 1H, CH-ala), 1.96–1.86 (m, 2H, H-2′, H-2′’), 
1.37 (t, J = 7.6, 3H, CH3 ester), 1.31–1.25 (m, 6H, CH3-thy, CH3-ala). 13C NMR (126 MHz, CDCl3) δ 
173.66, 173.36 (C-ala), 163.48 (C2, thy), 151.13, 151.10 (C1, thy), 150.29, 150.25 (C1, nosyl), 141.45, 
141.35 (C1, phenyl), 134.73, 134.67 (CH, thy), 129.86, 129.81 (CH, C2-6, nosyl), 129.15, 129.13 (CH, C2, 
C6, phenyl), 125.28 (CH, C4, phenyl), 124.84, 124.77 (CH, C3, C5, phenyl), 120.15, 120.11 (CH, C3, C5, 
nosyl), 120.06, 120.02, 111.36, 111.23 (C, C3, thy), 84.14, 84.00 (CH, C1′), 80.58, 80.52 (CH, C3′), 80.25, 
80.18 (CH, C4′), 63.17, 63.14 (CH2, C5′), 62.82, 62.79 (CH2, ethyl), 50.41, 50.20 (CH, ala), 39.18, 39.16 
(CH2, C2′), 20.94, 20.90 (CH3, ethyl), 14.12, 14.11 (CH3, ala), 12.58, 12.56 (CH3, thy). 31P NMR (202 MHz, 
CDCl3) δ 2.75, 2.48. MS (ESI)+: 705.1 [M + Na+]. HPLC: Rt: 15.88 min; Purity > 99%; [Gradient: (0′) 95% 
H2O/5% CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% 
CH3CN]. 
Synthesis of tert-butyl-3-((2R,4R,5R)-5-(((((tert-butoxycarbonyl)((S)-1-ethoxy-1-oxopropan-2-
yl)amino)(phenoxy)phosphoryl)oxy)methyl)-4-(((4-nitrophenyl)sulfonyl)oxy)tetrahydrofuran-2-yl)-5-methyl-
2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (7). MF: C37H47N4O17PS. MW: 882.83. The nosylated 
ProTide (6) (1 eq, 0.050 g, 0.073 mmol) was dissolved in pyridine (6 mL) at rt under nitrogen 
atmosphere. To the stirring solution, di(tert-butyl)dicarbonate (Boc2O) (1.3 eq, 0.021 mL, 0.020 g, 0.095 
mmol) was added dropwise and the reaction was stirred for 16h. The crude mixture was evaporated 
under reduced pressure and was purified by silica gel column chromatography (CH2Cl2/CH3OH 
gradient from 100% CH2Cl2 to 95% CH2Cl2) to give the final di-protected nosylated derivate 7 as a 
yellowish oil. Yield: 56%. Rf: 0.67 in 90% CH2Cl2/10% CH3OH as TLC system. 1H NMR (500 MHz, 
CDCl3) δ 8.47–8.36 (d, 2H, J = 2.2, Ar, nosyl), 8.17–8.08 (m, 2H, Ar, nosyl), 7.38 (m, 1H, Ar), 7.32–7.24 
(m, 4H), 7.17 (s, 1H, thy), 6.31–6.24 (m, 1H-H-1′), 4.51–3.75 (m, 7H), 2.78–2.43 (m, 1H, CH-Ala), 2.31–
2.23 (m, 1H-H-2′), 2.01 (m, 3H, CH3, thy), 1.53–1.49 (m, 9H, CH3, tert-butyl), 1.44 (m, 9H, CH3, tert-
butyl), 1.38 (t, J = 7.6, 3H, CH3, ester), 1.31 (m, 3H, CH3, ala). 13C NMR (126 MHz, CDCl3) δ 175.50, 
174.29 (C, ala), 161.32 (C2, thy), 150.13, 150.08 (C1, thy), 150.02, 150.00 (C1, nosyl) 143.51, 142.21 (C1, 
phenyl), 132.71, 132.23 (CH, thy), 130.68, 129.99 (CH, C2–C6, nosyl), 129.34, 129.5 (CH, C2, C6, 
phenyl), 126.28 (CH, C4, phenyl), 125.79, 124.85 (CH, C3, C5, phenyl), 120.15, 120.13 (CH, C3,C5, 
nosyl), 120.06, 120.02, 111.36, 111.23 (C, C3, thy), 84.13, 84.10 (CH, C1′), 80.78–80.77 (C-tert-butyl), 
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80.58, 80.52 (CH, C3′), 80.25, 80.18 (CH, C4′), 63.21, 63.20 (CH2, C5′), 62.79, 62.77 (CH2, ethyl), 50.39, 
50.30 (CH, ala), 39.18, 39.15 (CH2, C2′), 28.41–28.23 (CH3, tert-butyl), 20.94, 20.90 (CH3, ethyl), 14.12, 
14.11 (CH3, ala), 12.58, 12.56 (CH3, thy). 31P NMR: (202 MHz, CDCl3): δ 2.61, 2.53. MS (ESI+): 905.83 [M 
+ Na+]. HPLC: Rt: 17.1 min; Purity > 99%; [Gradient: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50% 
CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN]. 
Synthesis of tert-butyl-3-((2R,4S,5R)-5-((((N-((S)-1-ethoxy-1-oxopropan-2-yl)-3,3-
dimethylbutanamido)(phenoxy)phosphoryl)oxy)methyl)-4-[18F]fluoro-tetrahydrofuran-2-yl)-5-methyl-2,6-
dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (15). MF: C32H4518FN3O11P; MW: 696.70. Aqueous 
[18F]fluoride (2–8 GBq) produced by the cyclotron was trapped in a QMA cartridge and was then 
eluted through the cartridge by an aqueous solution of KHCO3 and Kryptofix in CH3CN. The 
resulting [18F]F-/KHCO3/Kryptofix complex was dried by an azeotropic distillation with anhydrous 
CH3CN (2 × 1 mL) under reduced pressure and a stream of nitrogen. A solution of the precursor 7 (10 
mg) in anhydrous CH3CN (1 mL) was added and the reaction was stirred for 30 min at 95 °C. The 
resulting reaction mixture was passed through an alumina cartridge to obtain the radiolabelled 
product 15. The reaction mixture was analysed by analytical radio HPLC: Rt: 15 min (analytical 
HPLC: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% 
H2O/5% CH3CN). 
Synthesis of ethyl ((((2R,3S,5R)-3-[18F]fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate (1). MF: C21H2718FN3O8P; MW: 498.43. 
To the Boc protected [18F]-radiolabelled ProTide (15), a solution of 2 N HCl (1 mL) was added and the 
reaction was stirred for 10 min. The solution was then neutralised with 2 N NaOH (1 mL). The crude 
mixture was then purified by semi-preparative HPLC and the desired compound was eluted after 35 
min at a flow rate of 3.5 mL/min using 70% H2O/30% CH3CN as mobile phase. The compound was 
then dried under a stream of nitrogen, taken up in saline and flushed through a sterility filter to 
obtain the aqueous solution of [18F]FLT ProTide (1). RCY of 15–30% (n = 5, decay-corrected from end 
of bombardment (EoB)), with high radiochemical purities (97%) and molar activities of 56 GBq/μmol. 
The total synthesis time was 130 min after the end of bombardment (EoB). The reaction mixture was 
analyzed by analytical radio-HPLC. Analytical HPLC: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50% 
CH3CN − (15′) 50% H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN); Rt: 9.5 min. 
3.4. Procedures and Analytical Data for the Synthesis of the [18F]FIAU ProTide 
Synthesis of 2′-deoxy-2′-α-fluoro-5-iodouridine (19). MW: 372.1; MF: C9H10FIN2O4. Iodine (1.2 eq; 1.24 
g; 4.87 mmol) and ceric ammonium nitrate (CAN) (1 eq; 2.23 g; 4.062 mmol) were added to a stirring 
solution of 2′-β-fluoro-2′-deoxyuridine (18) (2 eq; 2.0 g; 8.12 mmol) in anhydrous acetonitrile (50 mL). 
The mixture was stirred at 75 °C for 1 h and was then quenched with a saturated solution of Na2S2O3 
and concentrated under reduced pressure. The residue was then re-dissolved in ethyl acetate and 
washed twice with saturated NaCl. The organic layer was dried over MgSO4, filtered and 
concentrated to give compound 19 as a pale yellow solid. Yield: 60%. HPLC: Rt: 2.3 min; Purity > 95% 
(98% H2O/2% CH3CN). 1H NMR (500 MHz, DMSO-d6): δ 11.69 (s, 1H, NH), 8.53 (s, 1H, 6-CH), 5.86 
(d, J = 15.8, 1H, 1’-CH), 5.60 (d, J = 6.4, 1H, 3’-OH), 5.39 (t, J = 4.5, 1H, 3’-CH), 5.04 (dd, J = 5.2, 4.1, 1H, 
2’-CH), 4.18 (ddd, J = 23.4, 11.4, 7.2, 1H, 4’-CH), 3.90 (d, J = 8.2, 1H, 5’-OH), 3.85–3.79 (m, 1H, 5’-CH), 
3.63–3.58 (m, 1H, 5’-CH). 13C NMR (125 MHz, DMSO-d6): δ 167.88 (C=O), 165.01 (C=O), 145.02 (C-6), 
125.19 (CH, C-2’), 121.26 (CH, C-1’), 115.81 (CH, C-4’), 61.11 (CH, C-5), 57.30 (CH, C-3’), 45.87 (CH, 
C-5’). 19F NMR (470 MHz, DMSO-d6): δ −202.09. Spectroscopic data in agreement with literature [10]. 
Synthesis of benzyl(chloro(phenoxy)phosphoryl)-L-alaninate (20). MW: 353.73; MF: C16H17ClNO4P. 
Compound 20 was synthesised according to the standard procedure [16]. Anhydrous triethylamine 
(2 eq; 1.26 mL; 0.918 g; 9.08 mmol), phenyl dichlorophosphate (1 eq; 0.678 mL; 0.958 g; 4.54 mmol) 
and L-alanine benzyl ester hydrochloride salt (1 eq; 1.50 g; 4.54 mmol) were reacted to give compound 
20 as a yellowish oil. Yield: 88%. 1H NMR (500 MHz, CDCl3): δ 7.54–7.47 (m, 7H, Ar-H), 7.46–7.40 (m, 
3H, Ar-H), 5.27 (d, J = 8.4, 2H, CH2-ester), 4.69 (d, J = 9.9, 1H, NH), 4.13 (dd, J = 34.4, 29.8, 1H, CH-ala), 
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1.52 (m, 3H, CH3-ala). 31P NMR (202 MHz, CDCl3): δ 8.03, 7.75. Spectroscopic data in agreement with 
literature [29–31]. 
Synthesis of benzyl((((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate (21). MF: C25H26FIN3O9P; MW: 689.3. 
Compound 21 was prepared according to the standard procedure [16]. 1-(3-Fluoro-4-hydroxy-5-
(hydromethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione (19) (1 eq; 0.400 g; 1.07 
mmol) and NMI (5 eq; 0.424 mL; 0.439 g; 5.35 mmol) were reacted with benzyl 2-
(chloro(phenoxy)phosphorylamino)propanoate (3 eq; 1.05 g; 3.22 mmol) (20). The crude mixture was 
purified by silica gel column chromatography (CH2Cl2/CH3OH from 100% CH2Cl2 to 95% CH2Cl2) to 
obtain the product 21 as a yellowish oil. Yield: 10%. 1H NMR (500 MHz, CDCl3): δ 10.59 (s, 1H, 3-
NH), 7.89 (s, 1H, 6-CH), 7.53–7.48 (m, 2H, CH-phenyl), 7.45 (t, J = 8.0, 2H, CH-phenyl), 7.41–7.38 (m, 
2H, CH-benz), 7.17–7.15 (m, 2H, CH-benz), 7.13 (t, J = 8.0, 1H, CH-benzyl), 7.12 (t, J = 7.4, 1H, CH-
phenyl), 5.99 (m, 1H, 1’-CH), 5.79 (dd, J = 47.6, 4.6, 1H, 2’-CH), 5.14 (m, 2H, CH2-benz), 4.90 (m, 2H, 
5’-CH2), 4.39 (m, 1H, 4’-CH), 4.27 (m, 1H, 3’-CH), 4.19 (m, 1H, 3’-OH), 4.02 (m, 1H, NH-ala), 3.99 (m, 
1H, CH-ala), 1.29 (d, J = 7.0, 3H, CH3-ala). 13C NMR (125 MHz, CDCl3): δ 171.9 (C=O, ala), 168.12 (C=O, 
C-4), 144.18 (C=O, C-2), 149.0 (C-phenyl), 147.91 (C-benzyl), 145.5, 145.1 (CH, C-6), 128.31–121.48 (CH, 
Ar-C), 94.3 (C-5), 92.10 (CH, C-4’), 89.13 (CH, C-2’), 83.6, 82.97 (CH, C-1’), 81.08, 80.97 (CH2, C-ester), 
69.61, 68.14 (CH, C-3’), 67.23 (CH, C-5’), 52.8 (CH-ala), 21.98 (CH3-ala). 19F NMR (470 MHz, CDCl3): δ 
-200.91, -201.15. 31P NMR (202 MHz, CDCl3): δ 3.90, 3.86. MS (ESI)+: 690.3 [M + H+]. HPLC: Rt: 13.4 
min; purity > 97%; [Gradient: (0′) 95% H2O/5% CH3CN − (5′) 50% H2O/50% CH3CN − (15′) 50% 
H2O/50% CH3CN − (20′) 95% H2O/5% CH3CN]. 
Synthesis of (2R,3S,4R,5R)-5-((benzoyloxy)methyl)-3-[18F]fluoro-tetrahydrofuran-2,4-diyl-dibenzoate (17). 
MF: C26H2118FO7 MW: 463.4 Aqueous [18F]fluoride (4.11 GBq), produced by the cyclotron was trapped 
in a QMA cartridge before it was eluted with an aqueous solution of KHCO3 and Kryptofix in 
anhydrous CH3CN. The [18F]F-/KHCO3/Kryptofix complex was dried by co-evaporation with 
anhydrous CH3CN (2 × 1 mL) under reduced pressure and a stream of nitrogen. A solution of the 
triflate precursor (16) (10 mg) in anhydrous CH3CN (1 mL) was added to the reaction vial and the 
reaction was stirred for 30 min at 95 °C. The mixture was passed through an alumina cartridge to 
obtain the radiolabelled product 17 that was used for next step without further purification. The 
reaction mixture was analysed by analytical HPLC. Rt: 8.3 min (100% H2O). 
Synthesis of 5-iodo-2,4-bis((trimethylsilyl)oxy)pyrimidine (23). MF: C10H19IN2O2Si2; MW: 382.3. To a 
solution of 5-iodouracil (22) (1 eq; 10 mg; 0.042 mmol) in dichloroethane (500 μL), 
hexamethyldisilazane (11.4 eq; 100 μL; 0.0774 mg; 0.479 mmol) and TMSOTf (13.1 eq; 100 μL, 0.123 
mg; 0.549 mmol) were added. The mixture was stirred for 2 h at 85 °C and was used for next step 
without further purification. The purity of the compound was assessed by analytical HPLC (Rt = 6.9 
min; 88% H2O/12% CH3CN) and LC-MS ([M + H+]: 383.2). Spectroscopic data was in agreement with 
literature [10]. 
Synthesis of 1-((2R,3S,4R,5R)-3-[18F]fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-
iodopyrimidine-2,4(1H,3H)-dione ([18F]FIAU) (24). MF: C9H1018FN2O5 MW: 371.0. Compound 17 was 
delivered to a vial containing 2-4-bis(trimethylsilyl)-5-iodouracil (23). The mixture was then heated 
at 85 °C for 60 min. To this mixture, 0.5 M of NaOCH3 in CH3OH (1 mL) was then added and the 
reaction was stirred at 85 °C for another 5 min. The precipitate was then reconstituted in water (1 mL) 
and neutralised with 6 N HCl. The reaction mixture was analyzed by analytical HPLC showing the 
formation of the 2 anomers (α and β) of the 2′-deoxy-2′-fluoro-5-iodouridine. Analytical HPLC: 98% 
H2O/2% CH3CN; Rt: α anomer 2.1 min; β anomer 2.9 min). The anomeric mixture was then purified 
by semi-preparative HPLC and the target compound (24) was eluted after 7.3 min at a flow rate of 
3.5 mL/min using 20% CH3CN/80% H2O as mobile phase to obtain the final compound. HPLC: Rt: 
2.1 min; 98% H2O/2% CH3CN. Data in agreement with literature [10]. 
Synthesis of [18F]FIAU ProTide (2). MF: C25H2618FIN3O9P; MW: 688.3. To [18F]FIAU (24), NMI (0.1 mL) 
and a solution of benzyl-2-(chloro(benzyloxy)phosphorylamino)propanoate (20) (0.050 g) in 
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anhydrous THF (0.5 mL) were added together under nitrogen atmosphere. The reaction mixture was 
stirred at 50 °C for 20 min and then dried under a flow of nitrogen, re-dissolved in CH3CN and 
purified via semi-preparative HPLC. The compound 2 was eluted after 23 min at a flow rate of 3.5 
mL/min using 50% CH3CN/50% H2O as the mobile phase. The solvent was then removed from the 
mixture under a stream of nitrogen. The final product was then re-formulated in saline and flushed 
through a sterility filter to furnish a clean sterile aqueous solution of [18F]FIAU ProTide (2). 
Radiochemical reactions were carried out using starting activities between 4–15 GBq, leading to 
RCY’s of 1–5% (n = 7, decay-corrected from end of bombardment (EoB)), with high radiochemical 
purities (98%) and molar activities of 53 GBq/μmol. The total synthesis time was 240 min after the 
end of bombardment (EoB). Analytical HPLC: (0′) 95% H2O/5% CH3CN - (5′) 50% H2O/50% CH3CN- 
(15′) 50% H2O/50% CH3CN- (20′) 95% H2O/5% CH3CN); Rt: 12.3 min. 
4. Conclusions 
Phosphoramidate ProTide technology is a successful prodrug strategy to deliver nucleosides to 
their target sites, reducing toxicity issues and improving the potency of their parent nucleosides. 
Several fluorinated ProTides are currently being evaluated as anticancer and antiviral agents at 
different stages of clinical trials. PET imaging has the potential to provide the pharmacokinetic profile 
of certain drug candidates directly in vivo and therefore to predict the response to therapy. In this 
study we have developed the first radiochemical synthesis of the [18F]FLT ProTide (1) chosen as a 
model standard of the class of 3′-fluorinated ProTides. An automated late stage [18F]fluorination was 
tested on four different precursors with the best yields obtained when using a di-Boc protected nosyl 
derivative (7). The late stage fluorination and easy purification make this tracer a good candidate as 
a PET imaging probe with substantial potential for clinical application. 
[18F]FIAU ProTide (2) was synthesised as a model of the class of 2-‘fluorinated ProTides. Despite 
the early stage introduction of the fluorine-18, we have optimized the following steps involving the 
formation of the phosphoramidate bond. This optimization reduced the overall reaction time whilst 
maintaining a reasonable yield and high purity of the final compound.  
To our knowledge, this is the first time that [18F] radiolabelled ProTides have been synthesised. 
These radiotracers have the potential in preclinical models to further elucidate the in vivo mechanism 
of biodistribution and metabolism, as well as to be clinically translated for diagnostic and therapeutic 
evaluation purposes. 
Supplementary Materials: The following are available online. Figure S1. Internalization and metabolism of 
ProTides, bypassing the first-rate limiting step of the nucleoside analogues phosphorylation cascade; Figure S2. 
31P NMR stability study; Figure S3: E&Z modular lab sketch; Figure S4: Representative analytical HPLC 
chromatogram for the fluorination of the mesyl precursor 4; Figure S5: Representative analytical HPLC 
chromatogram for the fluorination of the tosyl precursor 5; Figure S6: Representative analytical HPLC 
chromatogram for the fluorination of the nosyl unprotected precursor 6; Figure S7: Representative analytical 
HPLC chromatogram of the fluorination of the nosyl protected precursor 7; Figure S8: Representative analytical 
HPLC chromatogram for the deprotection of the precursor 15 before purification; Figure S9: Representative 
analytical HPLC chromatogram for the fluorination of the sugar; Figure S10: Representative analytical HPLC 
chromatogram of the glycosylation reaction; Figure S11: Representative analytical HPLC chromatogram of the 
coupling reaction; Table S1: Radiolabelling attempts for the mesyl precursor (compound 4); Table S2: 
Radiolabelling attempts for the tosyl precursor (compound 5); Table S3: Radiolabelling attempts for the 
unprotected nosyl precursor (compound 6). 
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